Robert Cook, MD
Pulmonary Disease · Hendersonville, NCNPI 1356432561
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,957 of the $15,059 with a category attached, or 79.4%. Mylan Specialty L.p. accounts for 69.0% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $11,221 and has fallen 99.7% since, to $37 in 2025.
Across 87 payments — averaging $173.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$10K
- GSK$2K
- Sunovion Pharmaceuticals Inc.$1K
- Jazz Pharmaceuticals Inc.$158
- Sanofi-aventis U.S. LLC$145
- Boehringer Ingelheim$101
- plus $564 from 14 others
Across 2 payments — averaging $76,875 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$154K
What the payments were for
- Speaking & faculty fees$11,95779%
- Travel & lodging$1,60511%
- Food & beverage$1,3799%
- Education$1181%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 29 | $10,385 |
| GSK | 8 | $2,276 |
| Sunovion Pharmaceuticals Inc. | 9 | $1,431 |
| Jazz Pharmaceuticals Inc. | 2 | $158 |
| Sanofi-aventis U.S. LLC | 3 | $145 |
| Boehringer Ingelheim | 6 | $101 |
| Actelion Pharmaceuticals US, Inc. | 1 | $100 |
| Pfizer | 4 | $84 |
| Regeneron Healthcare Solutions, Inc. | 3 | $74 |
| AstraZeneca | 4 | $57 |
| Grifols USA, LLC | 3 | $54 |
| Electromed, Inc. | 6 | $47 |
| Shire North American Group Inc | 2 | $39 |
| Amgen | 1 | $20 |
| CSL Behring | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Merck | 1 | $13 |
| Philips North America LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$9,732
- TRELEGY ELLIPTA$2,200
- LONHALA MAGNAIR$1,250
- DUPIXENT$109
- XYREM$103
How this compares
$15,059 in reported general payments places this provider in the 85th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 391 | $301,425 |
| Dupixent SyringeDupilumab | 13 | $47,084 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 57 | $41,656 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 45 | $30,608 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $28,039 |
| SymbicortBudesonide/Formoterol Fumarate | 53 | $13,459 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $11,173 |
| Spiriva HandihalerTiotropium Bromide | 18 | $9,040 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 36 | $7,317 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $6,980 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 130 | $3,717 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $3,631 |
| Ventolin HfaAlbuterol Sulfate | 54 | $3,417 |
| Arnuity ElliptaFluticasone Furoate | 13 | $2,922 |
| Wixela InhubFluticasone Propion/Salmeterol | 28 | $1,835 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $2,276 | $369,974513 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $57 | $55,115110 claims |
| Boehringer IngelheimCombivent Respimat | $101 | $11,17319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Hendersonville
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
- Scott SkiboPinehurst$229K
- Jill OharWinston Salem$226K
- Priyank DesaiRocky Mount$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.